Strategy
Edison’s business strategy is to focus
first on inherited mitochondrial diseases where it can leverage both
non-dilutive capital and lower regulatory barriers in order to substantiate the value of
the Company’s platform and to serve as a beachhead for entering the non-orphan
mitochondrial drug space.